Diagnostic Immunoassays Could Spare Patients High-Risk Pancreatic Resection

LW Newsfeed

 

Researchers at Indiana University have confirmed the clinical utility of 2 laboratory tests that can distinguish benign pancreatic cancer lesions that mimic early signs of cancer and spare patients of unnecessary pancreatic cancer screenings or surgeries.

Pancreatic cancer is quite incurable, especially adenocarcinomas in the pancreas, which is the most common form of the disease, with a dismal 5-year survival rate of 12% to 14% if diagnosed early (stage IA to stage IB) – this falls back to 1% to 2% for patients with more advanced disease. However, a small fraction of patients harbor serous cystic neoplasms (SCNs), which are most often benign and may not need to be treated unless they grow or lead to symptoms. Read more . . .http://www.ajmc.com/newsroom/diagnostic-immunoassays-could-spare-patients-high-risk-pancreatic-resection


Conversation